Development of INER-PP-F11N as the Peptide-Radionuclide Conjugate Drug Against CCK2 Receptor-Overexpressing Tumors
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26146565 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ming-Cheng Chang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Isotope Application Research, National Atomic Research Institute, P.O. Box 3-27, Longtan, Taoyuan 325207, Taiwan. Hauptthemen laut MEDLINE: Receptor, Cholecystokinin B, Radiopharmaceuticals, Radioisotopes, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Taipei Veterans General Hospital, National Science and Technology Council of Taiwan.
Abstract (Originalsprache)
This work aimed to evaluate two albumin affinity structure-containing peptide-radionuclide conjugate drugs, INER-PP-F11N-1 and INER-PP-F11N-2, for the diagnosis/treatment of cholecystokinin receptor subtype 2 (CCK2R)-overexpressing cancers. We developed In-111- and Lu-177-labeled INER-PP-F11N radiopharmaceuticals and compared them with the current PP-F11N to investigate metabolic stability, biodistribution, SPECT/CT imaging, and therapeutic responses in CCK2R-expressing tumor xenograft mice. The metabolic stability of [111In]In/[177Lu]Lu-INER-PP-F11N remained above 90% for up to 144 h after labeling, indicating that the compound is highly stable under in vitro conditions. INER-PP-F11N showed 27% and 11% higher cellular uptake and internalization than PP-F11N, respectively. In vivo SPECT/CT imaging confirmed that INER-PP-F11N could accumulate at the tumor site of mice 24 h after receiving the two radiopharmaceutical agents. Biodistribution analysis revealed a significantly greater tumor uptake and reduced accumulation of INER-PP-F11N in the kidneys compared with PP-F11N. Furthermore, INER-PP-F11N significantly inhibited the growth of the CCK2R-overexpressing tumors in mice. The INER-PP-F11N radiopharmaceutical was superior as a theragnostic agent compared with the current PP-F11N. Our study suggests that INER-PP-F11N may be an innovative radiopharmaceutical agent for CCK2R-overexpressing tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Isotope Application Research, National Atomic Research Institute, P.O. Box 3-27, Longtan, Taoyuan 325207, Taiwan.
- Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei 112201, Taiwan.
- Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
- Department of Medical Imaging and Radiological Technology, Yuanpei University of Medical Technology, Hsin-Chu City 300102, Taiwan.
- Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei 100226, Taiwan.
- Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei 100226, Taiwan.
ORCID-Profile: Ming-Cheng Chang, Cheng-Liang Peng, Yuh-Feng Wang, Ying-Cheng Chiang
Förderung
- National Science and Technology Council
- Taipei Veterans General Hospital
- National Science and Technology Council of Taiwan
Zitieren
APA
Chang, M. C., Chen, C. T., Chiang, P. F., Tang, I. C., Peng, C. L., Wang, Y. F., Tai, Y. J., & Chiang, Y. C. (2025). Development of INER-PP-F11N as the Peptide-Radionuclide Conjugate Drug Against CCK2 Receptor-Overexpressing Tumors. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26146565
Vancouver
Chang MC, Chen CT, Chiang PF, Tang IC, Peng CL, Wang YF, et al. Development of INER-PP-F11N as the Peptide-Radionuclide Conjugate Drug Against CCK2 Receptor-Overexpressing Tumors. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26146565
BibTeX
@article{Chang2025,
author = {Chang, Ming-Cheng and Chen, Chun-Tang and Chiang, Ping-Fang and Tang, I-Chung and Peng, Cheng-Liang and Wang, Yuh-Feng and Tai, Yi-Jou and Chiang, Ying-Cheng},
title = {Development of INER-PP-F11N as the Peptide-Radionuclide Conjugate Drug Against CCK2 Receptor-Overexpressing Tumors},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26146565}
}
EUVIMED